News
Hosted on MSN1mon
Pfizer Faces Stock Slump Amidst Regulatory ChallengesThis investigation has raised concerns about potential legal and reputational ... the approval process for Pfizer’s vaccine candidates. Despite these challenges, Pfizer maintains a Moderate ...
Pfizer faces several headwinds, including patent cliffs, regulatory risks, and a setback in obesity drug development. Click ...
Although the immediate market response was negative, most pharmaceutical stocks recovered after Wall Street analysts ...
Pharmaceutical stocks, including Pfizer (NYSE: PFE ... rebounded after Wall Street analysts highlighted the significant legal challenges the order would face. The pharmaceutical industry has ...
In a landmark decision that challenges the European Commission’s transparency standards, the General Court of the European ...
May 14, 2025 Alnylam drops Covid vaccine patent case against Pfizer, BioNTech for now Biotech ... would be difficult to implement and face legal challenges. The United States and China on Monday ...
The European Court of Justice has upheld a transparency challenge over undisclosed text messages between EU Commission ...
Global pharmaceutical shares jumped in intraday trading Monday, reversing their pre-market declines, as investors anticipated ...
In this article, we are going to take a look at where Pfizer Inc. (NYSE ... These frameworks provide patients and developers with legal protection by simplifying liability standards for flawed ...
Pfizer Inc (NYSE:PFE) experienced a 6% operational revenue decline in Q1 2025, largely due to lower Paxlovid revenues and changes in Medicare Part D design. The company faces challenges from ...
The pressure to strategize on its pipeline comes as Pfizer prepares for new challenges. The company is bracing for a more than $15 billion loss over the next decade as patents for six major drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results